

What is claimed is:

5 1. A method for inhibiting the differentiation of an adipocyte cell comprising contacting a preadipocyte cell with an effective amount of an inhibitor of Interleukin 12 p35, whereby adipocyte differentiation is inhibited.

10 2. A method for inhibiting lipid accumulation in a cell comprising contacting a cell with an inhibitor of Interleukin 12 p35, whereby lipid accumulation in the cell is inhibited.

15 3. The method of claim 2 wherein the cell is a preadipocyte or adipocyte cell.

4. The method of claim 2 wherein lipid accumulation is triglyceride accumulation.

20 5. A method of treating a disease or condition associated with adipocyte differentiation in a mammal comprising administering to a mammal an effective amount of an inhibitor of Interleukin 12 p35, whereby adipocyte differentiation is inhibited.

25 6. The method of claim 5 wherein the disease or condition is obesity, cardiovascular disease, metabolic syndrome, diabetes, insulin resistance or cancer.

30 7. A method of treating a disease or condition associated with excess adipocytes in a mammal comprising

administering to a mammal an effective amount of an inhibitor of Interleukin 12 p35, whereby adipocyte differentiation is inhibited.

5 8. The method of claim 7 wherein the disease or condition is obesity, cardiovascular disease, metabolic syndrome, diabetes, insulin resistance or cancer.

10 9. A method of treating a disease or condition associated with lipid accumulation in a mammal comprising administering to a mammal an effective amount of an inhibitor of Interleukin 12 p35, whereby lipid accumulation is inhibited.

15 10. The method of claim 9 wherein the disease or condition is hyperlipidemia, obesity, cardiovascular disease, metabolic syndrome, diabetes, insulin resistance or cancer.

20 11. The method of claim 9 wherein lipid accumulation is triglyceride accumulation.

25 12. A method of treating a disease or condition associated with high triglyceride levels in a mammal comprising administering to a mammal an effective amount of an inhibitor of Interleukin 12 p35, whereby triglyceride accumulation is inhibited.

30 13. The method of claim 12 wherein the disease or condition is hypertriglycerolemia, obesity, cardiovascular disease, metabolic syndrome, diabetes, insulin resistance or cancer.

14. Use of an inhibitor of Interleukin 12 p35 in the manufacture of a medicament to inhibit the differentiation of adipocyte cells.

5 15. Use of an inhibitor of Interleukin 12 p35 in the manufacture of a medicament to inhibit lipid accumulation in a cell.

16. The use of claim 15 wherein lipid accumulation is
10 triglyceride accumulation.